|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet Jm, Bustamante J, Castells A, et
al: Natural history of untreated nonsurgical hepatocellular
carcinoma: rationale for the design and evaluation of therapeutic
trials. Hepatology. 29:62–67. 1999. View Article : Google Scholar
|
|
3
|
Cleary Sp, Jeck Wr, Zhao X, et al:
Identification of driver genes in hepatocellular carcinoma by exome
sequencing. Hepatology. 58:1693–1702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang J, Deng Q, Wang Q, et al: Exome
sequencing of hepatitis B virus-associated hepatocellular
carcinoma. Nat Genet. 44:1117–1121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guichard C, Amaddeo G, Imbeaud S, et al:
Integrated analysis of somatic mutations and focal copy-number
changes identifies key genes and pathways in hepatocellular
carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.PubMed/NCBI
|
|
7
|
Yamaga M, Kawai K, Kiyota M, Homma Y and
Yagisawa H: Recruitment and activation of phospholipase C
(PLC)-delta1 in lipid rafts by muscarinic stimulation of PC12
cells: contribution of p122RhoGAP/DLC1, a tumor-suppressing
PLCdelta1 binding protein. Adv Enzyme Regul. 48:41–54. 2008.
View Article : Google Scholar
|
|
8
|
Zhou X, Thorgeirsson SS and Popescu NC:
Restoration of DLC-1 gene expression induces apoptosis and inhibits
both cell growth and tumorigenicity in human hepatocellular
carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar
|
|
9
|
Shih YP, Liao YC, Lin Y and Lo SH: DLC1
negatively regulates angiogenesis in a paracrine fashion. Cancer
Res. 70:8270–8275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
|
|
11
|
Yuan BZ, Durkin ME and Popescu NC:
Promoter hypermeth-ylation of DLC-1, a candidate tumor suppressor
gene, in several common human cancers. Cancer Genet Cytogenet.
140:113–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim TY, Jong HS, Song SH, et al:
Transcriptional silencing of the DLC-1 tumor suppressor gene by
epigenetic mechanism in gastric cancer cells. Oncogene.
22:3943–3951. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Au SL, Wong CC, Lee JM, Wong CM and Ng IO:
EZH2-mediated H3K27me3 is involved in epigenetic repression of
deleted in liver cancer 1 in human cancers. PLoS One. 8:e682262013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jung SW, Park NH, Shin JW, et al:
Prognostic impact of telomere maintenance gene polymorphisms in
hepatocellular carcinoma patients with chronic hepatitis B.
Hepatology. 59:1912–1920. 2014. View Article : Google Scholar
|
|
15
|
Dong QZ, Zhang XF, Zhao Y, et al:
Osteopontin promoter polymorphisms at locus-443 significantly
affect the metastasis and prognosis of human hepatocellular
carcinoma. Hepatology. 57:1024–1034. 2013. View Article : Google Scholar
|
|
16
|
Dong X, Zhou G, Zhai Y, et al: Association
of DLC1 gene polymorphism with susceptibility to hepatocellular
carcinoma in Chinese hepatitis B virus carriers. Cancer Epidemiol.
33:265–270. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park SW, Durkin ME, Thorgeirsson SS and
Popescu NC: DNA variants of DLC-1, a candidate tumor suppressor
gene in human hepatocellular carcinoma. Int J Oncol. 23:133–137.
2003.PubMed/NCBI
|
|
18
|
Buongiorno P and Bapat B: Rho GTPases and
cancer. Prog Mol Subcell Biol. 40:29–53. 2005. View Article : Google Scholar
|
|
19
|
Gómez del Pulgar T, Benitah SA, Valerón
PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis:
evidence for a significant link. Bioessays. 27:602–613. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Zimonjic DB, Park SW, Yang XY,
Durkin ME and Popescu NC: DLC1 suppresses distant dissemination of
human hepatocellular carcinoma cells in nude mice through reduction
of RhoA GTPase activity, actin cytoskeletal disruption and
down-regulation of genes involved in metastasis. Int J Oncol.
32:1285–1291. 2008.PubMed/NCBI
|
|
21
|
Low JS, Tao Q, Ng KM, et al: A novel
isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor
growth and is frequently silenced in multiple common tumors.
Oncogene. 30:1923–1935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko FC, Yeung YS, Wong CM, et al: Deleted
in liver cancer 1 isoforms are distinctly expressed in human
tissues, functionally different and under differential
transcriptional regulation in hepatocellular carcinoma. Liver Int.
30:139–148. 2010. View Article : Google Scholar
|
|
23
|
Zhao B, Lu J, Yin J, et al: A functional
polymorphism in PER3 gene is associated with prognosis in
hepatocellular carcinoma. Liver Int. 32:1451–1459. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang Z, Zhou L, Wu LM, Xie HY, Zhang F and
Zheng SS: Combination of polymorphisms within the HDAC1 and HDAC3
gene predict tumor recurrence in hepatocellular carcinoma patients
that have undergone transplant therapy. Clin Chem Lab Med.
48:1785–1791. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wong CM, Yam JW, Ching YP, et al: Rho
GTPase-activating protein deleted in liver cancer suppresses cell
proliferation and invasion in hepatocellular carcinoma. Cancer Res.
65:8861–8868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Roessler S, Long EL, Budhu A, et al:
Integrative genomic identification of genes on 8p associated with
hepatocellular carcinoma progression and patient survival.
Gastroenterology. 142:957–966. e122012. View Article : Google Scholar :
|
